Aptose raises ~$13M in public offering and Hanmi PIPE for tuspetinib development

In connection with the completion of the Hanmi Investment, Aptose and Hanmi have entered into an agreement (the “ Funding Satisfaction Agreement ”), dated January 25, 2024, that provides that upon completion of the Hanmi Investment, Hanmi’s obligation to fund the second tranche of its investment pursuant to the subscription agreement entered by Aptose and Hanmi on September 6, 2023, will be deemed to be satisfied.

Investor Rights Agreement In connection with the Hanmi Investment, Aptose and Hanmi entered into an Amended and Restated Investor’s Rights Agreement (the “ Investor Rights Agreement ”), which amends and restates the Investor’s Rights Agreement entered by the parties on September 6, 2023.

Underwriting Agreement On January 25, 2024, Aptose Biosciences Inc. (“ Aptose ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Newbridge Securities Corporation, as Underwriter, pursuant to which Aptose agreed to issue and sell 4,912,280 common shares and 4,912,280 warrants to acquire common shares (the “ Warrants ”) at a combined public offering price of $1.71 per common share and Warrant (the “ Offering ”).

Subscription Agreement On January 25, 2024, Aptose entered into a subscription agreement (the “ Subscription Agreement ”) with Hanmi Pharmaceutical Co., Ltd., a corporation formed under the laws of the Republic of Korea, pursuant to which Aptose agreed to sell and issue to Hanmi and Hanmi agreed to purchase from Aptose $4.0 million of Aptose’s common shares and warrants to purchase common shares (the “ Hanmi Investment ”).